Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 5/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19730141 | 0.78 | PARP1 (0.44) | — | |
| SCHEMBL19730142 | 0.78 | NUDT1 (0.45) | — | |
| SCHEMBL13505462 | 0.77 | PDPK1 (0.38) | L3MBTL1MAPTPOLBTDP1NPSR1 | |
| SCHEMBL29863128 | 0.77 | PDPK1 (0.38) | L3MBTL1MAPTPOLBTDP1NPSR1 | |
| SCHEMBL13667386 | 0.76 | EGLN1 (0.39) | L3MBTL1SSTR4POLBTDP1NPSR1 | |
| SCHEMBL23120981 | 0.74 | JAK3 (0.36) | L3MBTL1MAPTPOLBTDP1NPSR1 | |
| SCHEMBL26068373 | 0.72 | MEN1 (0.34) | L3MBTL1MAPTPOLBTDP1NPSR1 | |
| SCHEMBL19730138 | 0.72 | TDP1 (0.33) | L3MBTL1MAPTPOLBTDP1NPSR1 | |
| SCHEMBL19730149 | 0.72 | L3MBTL1 (0.36) | L3MBTL1MAPTPOLBTDP1NPSR1 | |
| SCHEMBL21605151 | 0.71 | ATR (0.43) | SSTR4ATRPOLBTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | L3MBTL1 2316/4885SSTR4 2896/4885ATR 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.